

Article

Analgesic properties of opioid/NK1 multitarget ligands with distinct in vitro profiles in naive and chronic constriction injury (CCI)-mice

Joanna Starnowska, Roberto Costante, Karel Guillemin, Katarzyna Popiolek-Barczyk, Nga N. Chung, Carole Lemieux, Attila Keresztes, Joost Van Duppen, Adriano Mollica, John M. Streicher, Jozef Vanden Broeck, Peter W. Schiller, Dirk Tourwé, Joanna Mika, Steven Ballet, and Barbara Przewlocka

ACS Chem. Neurosci., **Just Accepted Manuscript** • DOI: 10.1021/acscchemneuro.7b00226 • Publication Date (Web): 12 Jul 2017

Downloaded from <http://pubs.acs.org> on July 14, 2017

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

**ACS Publications**

ACS Chemical Neuroscience is published by the American Chemical Society, 1155 Sixteenth Street N.W., Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Analgesic properties of opioid/NK1 multitarget ligands with distinct *in vitro* profiles in naive and chronic constriction injury (CCI)-mice

Joanna Starnowska,[†] Roberto Costante,^{‡,§} Karel Guillemin,[‡] Katarzyna Popiolek-Barczyk,[†] Nga N. Chung,[‡] Carole Lemieux,[‡] Attila Keresztes,[§] Joost Van Duppen,[¶] Adriano Mollica,[◇] John Streicher,[§] Jozef Vanden Broeck,[¶] Peter W. Schiller,[‡] Dirk Tourwé,[‡] Joanna Mika,[†] Steven Ballet,^{‡*} Barbara Przewlocka^{†*}

[†] *Institute of Pharmacology, Department of Pain Pharmacology, Krakow, Poland*

[‡] *Research Group of Organic Chemistry, Vrije Universiteit Brussel, Brussels, Belgium,*

[‡] *Department of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, Montreal, Canada,*

[§] *Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, U.S.A.*

[¶] *Animal Physiology and Neurobiology, Zoological Institute, Katholieke Universiteit Leuven, Leuven, Belgium.*

[◇] *Department of Pharmacy, "G. d'Annunzio" University, Chieti, Italy*

^{*} *Present address: IRBM Science Park s.p.a., Pomezia (RM), Italy*

Corresponding authors

Prof. Barbara Przewlocka
Polish Academy of Sciences,
Institute of Pharmacology,
Department of Pain Pharmacology.
12 Smetna Street, 31-343 Krakow, Poland
Phone, 0048126623398; E-mail: barbara.przewlocka@gmail.com

Prof. Steven Ballet
Research Group of Organic Chemistry,
Departments of Chemistry and Bioengineering Sciences,
Vrije Universiteit Brussel,
Pleinlaan 2, 1050 Brussel, Brussels, Belgium.
Phone: 0032-26293292; E-mail: Steven.Ballet@vub.be

ABSTRACT

The lower efficacy of opioids in neuropathic pain may be due to the increased activity of pronociceptive systems such as substance P. We present evidence to support this hypothesis in this work from the spinal cord in a neuropathic pain model in mice. Biochemical analysis confirmed the elevated mRNA and protein level of pronociceptive substance P, the major endogenous ligand of the neurokinin-1 (NK1) receptor, in the lumbar spinal cord of chronic constriction injury (CCI)-mice. To improve opioid efficacy in neuropathic pain, novel compounds containing opioid agonist and neurokinin 1 (NK1) receptor antagonist pharmacophores were designed. Structure-activity studies were performed on opioid agonist/NK1 receptor antagonist hybrid peptides by modification of the C-terminal amide substituents. All compounds were evaluated for their affinity and *in vitro* activity at the mu opioid (MOP) and delta opioid (DOP) receptors, and for their affinity and antagonist activity at the NK1 receptor. On the basis of their *in vitro* profiles, the analgesic properties of two new bifunctional hybrids were evaluated in naïve and CCI-mice, representing models for acute and neuropathic pain, respectively. The compounds were administered to the spinal cord by lumbar puncture. In naïve mice the single pharmacophore opioid parent compounds provided better analgesic results, as compared to the hybrids (max. 70% MPE), raising the acute pain threshold close to 100% MPE. On the other hand, the opioid parents gave poor analgesic effects under neuropathic pain conditions, while the best hybrid delivered robust (close to 100% MPE) and long lasting alleviation of both tactile and thermal hypersensitivity. The results presented emphasize the potential of opioid/NK1 hybrids in view of analgesia under nerve injury conditions.

Keywords: Hybrid peptides; neuropathic pain; acute pain; NK1 antagonists; opioid agonism.

INTRODUCTION

Neuropathic pain is a chronic pain state which results from a lesion or pathology of the central or peripheral nervous system; it affects up to 7-8% of the general population.³ Even though a variety of agents are used to reduce pain in neuropathy, less than half of patients report effective pain relief.⁴ However, one particular strategy, the design of drugs with bi- or even multifunctional activity, offers a promising strategy to treat neuropathic pain. This strategy addresses the complex nature of this pain type, which is associated with pathological overactivation of endogenous pronociceptive systems as a maladaptive response to the somatosensory system injury.⁵⁻⁶ Bi- or multifunctional agents are able to interact

independently with two or more targets (such as different types of receptors) to achieve the desired therapeutic effect.⁷⁻¹⁰ In particular, hybrid compounds designed as potential therapeutic agents in neuropathic pain are able to activate the opioid system – to achieve an antinociceptive effect – and hamper the activation of pronociceptive systems, to correct an imbalance between anti- and pronociception after repetitive opioid administration. In consequence, such hybrids are expected to provide an efficacious analgesic effect with lowered risk of adverse events.

In previous studies on rats, we obtained promising results for hybrids acting as opioid agonists and neurokinin-1 (NK1) receptor antagonists.² In the present study we performed biochemical analyses in mice under neuropathic pain conditions, which provide a basis for the observations described above: the inefficacy of morphine to alleviate neuropathic pain is not due to a reduced expression of the mu opioid peptide (MOP) receptor, but rather related to counteraction due to an increased release of the pronociceptive substance P.¹¹ This conclusion motivates further studies to design new opioid agonist/NK1 receptor antagonists to treat neuropathic pain, especially with regard to the influence of the relative potencies of the included pharmacophores on *in vivo* efficacy. Therefore, in the current study, eight new hybrids were prepared (compounds **6 – 13**, **RCCHM1-8**, Table 1), and on the basis of their *in vitro* pharmacological profile, the analgesic action of two of them in mice was compared to that of a reference opioid **1** (**AN81**) and hybrid **3** (**SBCHM1**), both of which were tested previously on rats.² This comparison allowed a selection of the best hybrid structures for testing of effective analgesia in mouse models of acute and neuropathic pain. Moreover, it also provides insight into correlations between chemical structure and analgesic efficacy in different behavioral tests.

RESULTS AND DISCUSSION

Development of neuropathic pain and biochemical changes in the spinal cord, at a selected time point after chronic constriction injury (CCI) to the sciatic nerve in mice.

Development of neuropathic pain.




Figure 1. Development of hypersensitivity to tactile stimuli, as measured by the von Frey test (panel A; cut-off: 6 g) and thermal stimuli, as measured by the cold plate test (panel B; cut-off: 30 s) at different time-points in naïve (black dotted line) and CCI-subjected (red line) mice

Twenty four hours after performing the chronic constriction injury (CCI), mice developed hypersensitivity to tactile (von Frey test) and thermal (cold plate test) stimuli (Fig.1, panels A and B, respectively). This was manifested as a significant decrease of the response threshold in comparison with naïve mice. Seven days after performing the nerve damage, CCI-mice reacted to tactile stimuli (paw withdrawal) in the von Frey test at the mean force of 1.05 ± 0.3 g (cut-off: 6 g). Tactile stimuli up to 6 g are neutral for healthy mice, and hence naïve animals do not react to it. Paw withdrawal of CCI-mice in the cold plate test was observed on average after 5.6 ± 0.2 seconds (cut-off: 30 s). Naïve mice react after 26.9 ± 1.7 s on average. The greatest manifestation of hypersensitivity symptoms was observed between the 7th and 14th day after nerve injury (Fig. 1).

Changes in mRNA and protein levels of MOP, DOP and NK1 receptors, and in substance P level in the lumbar spinal cord of mice at day 7 after CCI

To investigate biochemical changes that parallel behavioral hypersensitivity and clarify the causes of the inefficacy of opioids to treat neuropathic pain, a quantification of the μ -opioid (MOP), δ -opioid (DOP) neurokinin 1 (NK1) receptors and substance P mRNA abundance and

their protein level was performed using qRT-PCR and Western Blot methods in the lumbar part of the spinal cord of mice, on the 7th day after CCI.




Figure 2: The mRNA (left panel) and protein (right panel) level of MOP, DOP and NK1 receptors and substance P in lumbar spinal cord of CCI-exposed mice, on the 7th day after surgical procedure. The data are presented as the mean \pm SEM. Intergroup differences were analyzed using ANOVA followed by Bonferroni's multiple comparison tests. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ indicate significant differences compared with naive mice.

The qRT-PCR results on day 7 following CCI revealed no changes in MOP and DOP receptor mRNA level in the spinal cord. Whereas the protein expression level was also not altered in the case of the MOP receptor, DOP receptor protein ($p < 0.05$ vs control) levels increased significantly on the injury site. A slight increase on the contralateral side did not reach significance (**Fig. 2 D**). A decrease in the NK1 receptor mRNA level in the lumbar spinal cord, on the ipsilateral ($p < 0.001$ vs control) and contralateral ($p < 0.05$ vs control) side was observed. However, the protein level of NK1 receptor was significantly diminished only on the ipsilateral side ($p < 0.05$ vs control) (**Fig. 2 F**). The level of substance P mRNA was increased on the ipsilateral ($p < 0.01$ vs control), but not the contralateral side, which was accompanied by a corresponding change in protein level ($p < 0.05$ vs control) (**Fig. 2 G,H**).

The injury-induced development of neuropathic pain is clearly accompanied by changes in mRNA and protein levels of both the opioid and neurokinin systems, as measured on day 7 after injury. It should be noted that there is also a report demonstrating an increase of SP-encoding gene TAC1 mRNA level in rats at day 3 after injury in the dorsal root ganglia (DRG), without changes in the spinal cord.¹² The changes demonstrated in our experiments on mice support the pronociceptive activity of substance P. The increase in levels of both mRNA and especially functionally active substance P on the injury side is balanced by a lower expression of the NK1 receptor, seen as a lower level of the mRNA on both sides and of protein on the lesion side. This indicates an increased activity of the pronociceptive system in the development of injury-induced neuropathic pain. In contrast, there is a significant increase of the DOP receptor protein on the ipsilateral side after damage. Moreover, neither mRNA nor the protein of MOP receptor changes at the spinal cord level at day 7 after sciatic nerve injury. Obara et al. did not observe any changes in mRNA of MOP in the spinal cord of CCI-rats at days 3 and 14 after injury.¹³ However, several lines of evidence have shown a reduction of MOP receptor at the spinal cord level after nerve injury in rats and mice.¹⁴⁻¹⁵ The observed discrepancies may result from the different methods of spinal cord dissection used to collect lumbar part for biochemical analysis. In the mentioned work of Obara,¹³ no significant changes in mRNA of DOP receptor (3 and 14 days after CCI) were observed, which is in line with data presented here for day 7. Nonetheless, this report is the first to show that protein levels of DOP receptor are elevated in the ipsilateral side of the spinal cord of CCI-mice 7 days after injury. In 2007 Kabli and Cahill observed an up-regulation of the DOP protein level in DRG 14 days after sciatic nerve injury.¹⁶ It was suggested that this increase was correlated with DOP trafficking.


Our results support the hypothesis of altered NK1 system activation under neuropathic pain conditions, which together with no changes in MOP receptor activity, increases the importance of the pronociceptive system. Altogether, these findings provide the rationale for the development of bifunctional opioid compounds containing an NK1 system-targeting component as drug candidates for neuropathic pain treatment.

Compound Design and Synthesis

As a starting point for the current study, bifunctional hybrids **3** (**SBCHM1**, H-Dmt-D-Arg-Aba-Gly-*N*Me-3',5'-(CF₃)₂-Bn) and **4** (**KGCHM2**, H-Dmt-D-Arg-Aba-β-Ala-*N*MeBn), which are a combination of an opioid agonist pharmacophore and NK1 receptor antagonist pharmacophore to attenuate pronociceptive action, were selected.¹⁻² Both compounds have a *N*-methylated amide group in the *C*-terminal NK1 pharmacophore, which is essential for affinity and antagonism at the NK1 receptor.¹ Whereas secondary amide groups adopt exclusively a *trans* conformation, tertiary amides exist as a mixture of *cis* and *trans* isomers with a reduced activation energy for rotation.¹⁷ Since a large percentage of *cis* isomers (18-22%) was found in an earlier study of NK1-ligands, this configuration might be important for activity.¹⁸⁻¹⁹ Hence, the introduction of *N*-alkyl groups larger than methyl may result in higher populations of the *cis* amide bond. We previously showed that the introduction of an *N*-isobutyl group resulted in a loss of affinity at the NK1 receptor.² Therefore, the smaller cyclopropyl group was evaluated in an attempt to avoid unfavorable steric interactions with the NK1R (compounds **6** to **8**, **RCCHM1/2/8**, Table 1). Additionally, a conformational constraint was introduced by using the isoindoline amide (compounds **9** and **10**; **RCCHM4/5**). This leads to identical *cis* and *trans* isomers and reduces the number of rotatable bonds, which could improve membrane permeability.²⁰ Aside from the bis(trifluoromethyl)benzyl substituent, the *ortho*-methoxybenzyl group often occurs in small molecule NK1 receptor antagonists,²¹ and hence this substituent was investigated as well. Finally, because NK1 receptor antagonists have been shown to mostly possess two key aromatic systems, which are in a stacked 'L' or 'T' configuration,²¹ we investigated whether a change from the *C*-terminal benzyl amide to naphthalen-2-yl-methyl amide could improve stacking of the benzene ring within the amino-benzazepinone (Aba) scaffold with the larger naphthalene ring (cf. compounds **12** and **13**).

The syntheses of the opioid tetrapeptide Dmt-D-Arg-Aba-Gly-NH₂ **1** (AN81) and the reference hybrid **3** (SBCHM1) were reported previously.¹ For the preparation of hybrids **6** – **13**, protected tetrapeptide analogs Boc-Dmt-D-Arg(Pbf)-Aba-Gly-OH and Boc-Dmt-D-Arg(Pbf)-Aba-β-Ala-OH were assembled as reported by a standard solid phase method.² Next, the secondary amines were coupled to the two Boc-protected tetrapeptide analogs using DIC/HOBt. These secondary amines were prepared either by reductive amination of cyclopropylamine with benzaldehyde, using sodium cyanoborohydride, or by alkylation of cyclopropylamine with 2',5'-bis(trifluoromethyl)benzyl chloride, or of methylamine with 2-(bromomethyl)naphthalene. The isoindoline amine was commercially available.

Table1: Structure of the reference compounds **1 – 5** and of the new hybrids **6 – 13**.



Compound number (code)	n	R ¹	R ²
1 (AN81) ¹	1	H	H
2 (KGOP1) ²	2	H	H
3 (SBCHM1) ¹	1		
4 (KGCHM2) ²	2		
5 (KGCHM5) ²	1		
6 (RCCHM1)	2		
7 (RCCHM2)	2		
8 (RCCHM8)	1		
9 (RCCHM4)	2		
10 (RCCHM5)	1		
11 (RCCHM7)	1		
12 (RCCHM3)	2		
13 (RCCHM6)	1		

Binding and *in vitro* activity at the MOP, DOP and NK1 receptors

All compounds were evaluated for their affinity and *in vitro* activity at the MOP and DOP receptors, and for their affinity and antagonist activity (except for the parent opioid **1** and **2** compounds) at the NK1 receptor. The results are summarized in Table 2.

Table 2: Binding and *in vitro* activity at the opioid and NK1 receptors. Results of the compounds selected for *in vivo* testing are shown with a grey background.

Compound no.	Structure	NK ₁ R ^a	NK ₁ R	GPI ^c	MVD ^c	MOP ^d	DOP ^d
		K _i (nM)	pA ₂ ^b	IC ₅₀ (nM)	IC ₅₀ (nM)	K _i (nM)	K _i (nM)
1^e	H-Dmt-D-Arg-Aba-Gly-NH ₂	nd	nd	0.32	0.42	0.15	0.60
2^f	H-Dmt-D-Arg-Aba-β-Ala-NH ₂	nd	nd	0.80	0.24	1.34	17.0
3^e	H-Dmt-D-Arg-Aba-Gly-NMe-3',5'-(CF ₃) ₂ -Bn	0.5	7.80	8.51	43.3	0.42	10.4
4^f	H-Dmt-D-Arg-Aba-β-Ala-NMe-Bn	13.0	6.44	1.86	2.16	0.08	0.28
5^f	H-Dmt-D-Arg-Aba-Gly-NMe-Bn	1530	nd	5.97	8.64	0.09	2.35
6	H-Dmt-D-Arg-Aba-β-Ala-NcPr-3',5'-(CF ₃) ₂ -Bn	735	5.36	18	16	47	190
7	H-Dmt-D-Arg-Aba-β-Ala-NcPr-Bn	520	5.20	19	6.6	2.7	66
8	H-Dmt-D-Arg-Aba-Gly-NcPr-Bn	95	5.50	10	11.2	0.30	68
9	H-Dmt-D-Arg-Aba-β-Ala-isoindoline	>10.000	0.25	5	2.1	0.20	16
10	H-Dmt-D-Arg-Aba-Gly-isoindoline	3495	3.16	7.3	8.0	0.06	81
11	H-Dmt-D-Arg-Aba-Gly-NMe-2'-OMe-Bn	501	4.84	5.0	2.4	0.90	26
12	H-Dmt-D-Arg-Aba-β-Ala-NMe-2'-methylenenaphthyl	612	7.01	9.0	4.0	0.40	44
13	H-Dmt-D-Arg-Aba-Gly-NMe-2'-methylenenaphthyl	709	5.44	3.0	10.0	2.8	228

^a Binding affinities of compounds for hNK1 receptors were determined by displacement of [³H]substance P from binding sites in hNK1 receptors expressed in CHO cells. ^b The pA₂ values were calculated using Schild's equation.²² ^c The GPI functional assay is representative of MOP receptor activation, whereas the MVD is a DOP receptor-representative assay. ^d Binding affinities of compounds for MOP and DOP receptors were determined by displacement of [³H]DAMGO ([D-Ala²,NMePhe⁴,Gly-ol⁵]enkephalin) and [³H]DSLET ([D-Ser²,Leu⁵]enkephalin-Thr⁶), respectively, from rat brain membrane binding sites.^{e,f} Data from Ballet *et al.*¹ and Guillemyn *et al.*² respectively. nd: not determined.

Our previous studies showed that when Gly⁴ (n = 1) in **3** was substituted by a β-alanine residue (n = 2) and the bis-trifluoromethyl substituents were removed to give **4**, binding

affinities to MOP and DOP receptors improved. Also, the activity in the GPI and MVD assays (representative of MOP and DOP receptor agonism, respectively) improved in **4**, but affinity for the NK1 receptor and antagonism at the NK1 receptor was reduced (K_i shifted from 0.5 nM to 13 nM and pA_2 shifted from 7.80 to 6.44).² Moreover, we had demonstrated that the replacement of the *N*-methyl (R^2) substituent by a bulky *isobutyl* substituent in either **3** or **4** resulted in a dramatic loss in NK1 receptor affinity.² Here, we observe that replacement of the *N*-methyl in the β -Ala-containing **4** by a *N*-cyclopropyl group, which is smaller than *isobutyl*, unfortunately also resulted in reduced binding and activity at the opioid receptors, especially at DOP in **6** and **7**. Concomitantly, binding affinity and antagonism at the NK1 receptor substantially dropped. The same substitution in the Gly-containing analog **5**,² gave **8** with somewhat reduced MOP receptor affinity (K_i = 0.3 versus 0.09 nM), but especially reduced DOP receptor affinity (K_i = 68 versus 2.35 nM) and increased, but still rather low NK₁ affinity (K_i 95 versus 1530 nM) with a very modest pA_2 value of 5.50. Additionally, the *N*-methylbenzyl substituent in **4** was replaced by an isoindoline group. This modification, leading to **9**, results in identical *cis/trans* isomers and limits the amount of rotatable bonds (nRot reduced by two units),²⁰ which could potentially improve binding and absorption. Surprisingly, it resulted in a detrimental drop in NK1 antagonism (pA_2 : 6.44 to 0.25), while retaining good activity and affinity at the opioid receptors. The glycine equivalent, **10**, similarly has strongly reduced NK₁ receptor affinity and antagonism, but importantly it yielded a ligand with a binding affinity for MOP receptor of 60 pM, while DOP receptor affinity was lower than that of **9** (K_i of 81 vs 16 nM). Addition of a methoxy-group in *ortho*-position of the *N*-benzyl moiety in **11** did not result in good affinity and antagonism at the NK1 receptor, but again good activity and affinity was observed at the opioid receptors. As mentioned above, the insertion of larger aromatic groups might lead to increased aromatic stacking to provide the relative 'L'- or 'T' orientations of these groups, which was reported to be required for potent antagonism at the NK1 receptor.²¹ The NK1 receptor antagonism of **12**, containing a naphthyl instead of a phenyl substituent, was in line with this hypothesis. Comparison of the *N*-methylbenzyl **4** with the naphthyl derivative **12** indeed showed an increased pA_2 (from 6.44 to 7.01), despite a lower NK1 receptor affinity, while retaining low nanomolar activity at the opioid receptors. However, the Gly⁴ analogue **13** displayed a two orders of magnitude lower NK1 receptor antagonism (pA_2 of 7.01 vs. 5.44). It can be concluded that the nature of the *N*-substituent in these hybrids is crucial for the NK1 receptor, whereas the opioid receptors are much more tolerant to changes.

Based on these results, the naphthyl substituted analogs **12** and **13** were selected for further *in vivo* evaluation. Their properties were compared to the reference opioid parent **1** and hybrid **3**.

Behavioral study

Effect of the selected hybrids and their parent compounds on motor performance after i.t. administration in naïve mice

A dose of 1 µg/5µl per animal (i.e., ca. 1 nmol of hybrids **3**, **12**, **13**, and 1.3 nmol for opioids **1** and **2**) was chosen to assess its influence on motor performance of naïve mice in the RotaRod test (**Fig. 3**). Vehicle, hybrids **3**, **12**, **13** and their reference opioid compounds **1** and **2** were administered intrathecally; after 30 min, motor performance was assessed by the RotaRod test. None of the hybrids influenced motor performance of naïve mice. In contrast, reference opioid compounds **1** and **2** significantly hampered motor performance at the dose of ca. 1.3 nmol.




Figure 3. The effect of intrathecal (i.t.) administration of ca. 1-1.3 nmol of reference opioid compound **1** and its hybrid **3** and reference opioid compound **2** and its hybrids **12**, **13** on motor performance, as compared to Vehicle (Veh)-treated group, measured 30 min after administration by the RotaRod test in naïve mice.

The antinociceptive effect of selected hybrids and their parent opioid compounds after i.t. administration in naïve mice

The effect of hybrid **3** and its reference opioid **1**, and hybrids **12** and **13**, and their reference opioid **2** on the pain threshold to a thermal stimulus was investigated in naïve mice after

administration to the spinal cord. Opioid agonist **1** was able to raise the latency of the response to thermal stimuli (as measured by the tail-flick test) at a dose as low as 0.0013 nmol. At the highest dose tested (1.3 nmol), it provided a robust analgesic effect (close to 100% MPE) lasting up to 180 minutes after administration (**Fig. 4A left panel**). In contrast, the effect of hybrid **3** proved to be weaker than its parent compound (**Fig. 4B left panel**).

Opioid agonist **2** also gave longer-lasting analgesia at doses 0.1 – 1 nmol, though the effect provided by the highest 1 nmol dose tested was no greater than 80% MPE (**Fig. 4C left panel**). The two hybrids **12** and **13** gave long-lasting analgesic effects in acute pain, yet weaker responses were noticed (60-70% MPE) in spite of raising the doses up to ca. 10 nmol (**Figure 4D,E left panel**). This is in line with the weaker agonism at the opioid receptors of the hybrids, compared to **1**. Among all hybrids **13** was the one that provided the longest lasting effect ($p < 0.001$ vs vehicle at 180 min after administration), even though the effect did not rise above 50% MPE. (**Fig. 4E left panel**).




Figure 4. Effect of intrathecal (i.t.) administration of the reference opioid **1** and its hybrid **3** (A+F, B+G), and reference opioid **2** and its hybrids **12** and **13** (C+H, D+I, E+J) on pain threshold as measured by the tail-flick test in naïve mice (left panel), and hypersensitivity as measured by the von Frey and cold plate tests in CCI-exposed mice (right panel). The

hypersensitivity tests were performed on mice (6 – 8 animals per group) between the 7th-14th day after chronic constriction injury (CCI). Inter-group differences were analyzed by ANOVA with Bonferroni's Multiple Comparison Post-Hoc Test. The results are presented as percentages of the maximal possible effect (%MPE). The horizontal line in the figure separates parents and hybrid compounds including Gly⁴ vs. β -Ala⁴ residues. The doses are presented in nmol/5 μ l/animal. *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle-treated group (Veh).

The antinociceptive effect of selected hybrids and their parent compounds after i.t. administration in CCI-subjected mice

All investigated compounds influenced the response latency in the neuropathic pain model. As expected, the opioid structures **1** and **2** demonstrated a limited efficacy in both tests (**Fig. 4 F,H right panel**). Reference opioid **1** raised the response threshold in both tests, yet a weak analgesic effect was observable - the response was not higher than 30% MPE in spite of significant dose increments in the cold plate test, and not higher than 40% MPE in the von Frey test (**Fig. 4F right panel**). In the case of compound **2**, which is the reference opioid for hybrids **12** and **13**, no influence on the response threshold in the von Frey test was observed at all. In addition, its analgesic action in the cold plate test was seriously limited, no more than 20 %MPE (**Fig. 4H right panel**).

Hybrid **3** was the weakest analgesic of the examined hybrids, but it was still able to raise the response latency to ca. 60% MPE (**Fig 4G right panel**). Hybrid **13** proved to be the most efficient analgesic in both tests. Application of the lowest tested dose (i.e. 0.1 nmol) raised the response threshold to ca. 70% MPE in the von Frey test. This dose did not significantly influence the response in the cold plate test, but raising the dose to 10 nmol resulted in a robust analgesic effect (close to 100% MPE) for both tactile and thermal stimuli (**Fig. 4J right panel**). The effect of hybrid **12** was weaker in both tests (**Fig. 4I right panel**).

Nonetheless, hybrid **3** was the only compound (p < 0.05) showing activity up to 180 min in the von Frey test when administered at the moderate dose of approximately 1 nmol (**Fig 4G right panel**). Hybrids **12** and **13**, at the equivalent moderate dose, provided a shorter lasting effect, not observable 180 min after administration (**Fig. 4I,J right panel**). Of note, **13** was

the only compound that provided an effect at 180 min after administration in the cold plate test (**Fig. 4J, right panel**), but only at the highest dose of 10 nmol.

We then examined the effects of opioid parents and hybrid compounds in an acute pain model in naïve mice. In contrast to the neuropathic pain results, the opioid parent structure **1** (**AN81**) induced a superb analgesic effect in the acute pain model. It was efficacious at doses as low as 0.001 nmol/5µl/animal ($p < 0.05$ vs vehicle) and it provided almost 100% MPE at the dose of 1 µg. The effect of this dose was still very robust ($>80\%$ MPE) at 180 min after i.t. administration. The opioid parent structure **2** demonstrated similar properties. However, both of the reference opioids demonstrated significantly hampered action in the neuropathic pain model: **1** exhibited a modest effect in the von Frey test (ca. 40% MPE at 30 min), where **2** was not efficacious at all, and showed a poor effect in the cold plate test ($<30\%$ MPE). This effect was no longer present 30 min after administration. This indicates that both **1** and **2** lose their efficacy under neuropathic pain conditions, which stands in line with the results of previous experiments on rats,² as well as with the well-documented phenomenon of limited analgesic activity of opioids under neuropathic pain conditions.²³⁻²⁶ All hybrid compounds provided a lowered analgesic effect ($<70\%$ MPE) in the tail-flick test up to 180 min after administration, as compared to the parent opioids. Compound **3** was the strongest analgesic among all hybrids at the highest dose 9.5 nmol/5µl/animal ($p < 0.001$ at 30 min after administration). On the other hand, hybrids **12** and **13** were able to provide an analgesic effect at the relatively low dose 0.1 nmol up to 180 min after administration. In contrast, **3** provided the weakest effect in the neuropathic pain model, as compared to **12** and **13**. At the highest dose 9.5 nmol, hybrid **3** was more potent in the cold plate test than in the von Frey test 30 min after administration. In the von Frey test, **3** was the only compound that induced an analgesic effect at the dose 1 µg (ca. 1 nmol) up to 180 min after administration.

Summing up, the addition of the NK1 receptor antagonist pharmacophore to the opioid sequence counteracted the loss of efficacy in a neuropathic pain model, as seen by the differences in opioid parent structure activity in naïve and neuropathic mice (**Fig 4 A, C**). It is very interesting that hybrid **3** also loses its effectiveness, although its effect at a short time after administration is close to that in naïve mice. In contrast to hybrid **3**, two hybrids of the novel series (i.e. compounds **12** and **13**) exhibit stronger effects in neuropathic pain than in naïve mice. Paradoxically, these two hybrids have a much weaker binding to the NK1 receptor compared to **3**, with similar binding to the opioid receptors. It can be assumed that

spinal NK1 receptors are less significant for that effect than receptors located in other structures of the pain pathway, but this would require further investigation.

Taking into consideration all behavioral results, **13** seems to exhibit the most beneficial pharmacological profile as an analgesic drug: it provides a moderate (~60% MPE) effect in attenuating acute pain, as measured in three time points after administration. In addition, its analgesic effect in CCI-exposed mice is highly efficacious. It produced a robust response in both the von Frey and cold plate tests, with the effect of the highest dose (10 nmol/5µl/animal) close to 100% MPE in both tests.

As observed before, the best analgesic compounds have high MOP/DOP receptor agonist potency and efficacy, but to be an effective analgesic for neuropathic pain it must be combined with an NK1 receptor antagonist. In contrast to the MOP/DOP potency and efficacy, NK1 potency and efficacy does not necessarily need to be very high.^{2, 27} The same applies to motor performance, wherein the hybrids do not show impaired motor performance as clearly manifested for the parent compounds. It seems that for both these opioid effects the NK1 component is important, but not the strength of its (*in vitro*) antagonism. This is important information when searching for new analgesics to be used for neuropathic pain treatments.

CONCLUSIONS

In the present study we demonstrated the analgesic effect of bifunctional hybrids, both in naïve mice and in a neuropathic pain mouse model. Our results support the concept of altered NK1 system activation under neuropathic pain conditions which, in parallel with no changes in MOP receptor mRNA level, increases the importance of the NK1 pronociceptive system. These findings justify the strategy to use opioid compounds, containing an NK1 system-targeting component.

We have studied the influence of the *N*-terminal amide substituents in opioid agonist – NK1 receptor antagonist hybrids. Whereas these substituents do not dramatically influence the affinity and agonist activity at the MOP and DOP receptors, their influence on NK1 receptor affinity and antagonism is pronounced. The isoindoline-substituted analogs **9** and **10** are very potent MOP/DOP receptor agonists, but their activity at the NK1 receptor is abolished. The *N*-Me-2-methylenenaphthyl analogs **12** and **13** have the best balance of opioid agonism/NK1 receptor antagonism as determined in the *in vitro* study.

As a consequence, we assessed the analgesic effects of three distinct opioid agonist – NK1 receptor antagonist hybrid compounds **12**, **13** and **3**, after intrathecal (i.t.) administration in mice in an acute and neuropathic pain model. Each of the tested compounds demonstrates unique analgesic properties, as determined in the different tests. Two hybrids of the novel series (i.e. compounds **12** and **13**) exhibit stronger effects in the neuropathic pain models, as compared to an antinociceptive assessment in naive mice. Paradoxically, these two hybrids have a much weaker NK1 receptor binding affinity as compared to the initial lead structure **3**, with similar binding affinities at the opioid receptors. It can be suggested that spinal NK1 receptors are less significant for that effect than receptors located in other structures of the pain pathway, but this would require further investigation. As previously demonstrated, the combination of a MOP/DOP agonist with a NK1 antagonist in a bifunctional compound can delay or suppress analgesic tolerance,²⁸⁻²⁹ and transport an otherwise non-permeable NK1 antagonist into the brain.² In addition, the present results demonstrate that weak NK1 antagonism is sufficient for potent analgesia in neuropathic pain models. This avoids the use of high doses of a NK1 antagonist alone, which has been shown to induce neurotoxicity in rats.²⁷

In brief, the addition of the NK1 receptor antagonist pharmacophore to the opioid sequence counteracted the loss of efficacy in a neuropathic pain model, as seen in differences in opioid parent structure activity in naive and neuropathic mice. Altogether, these findings justify a continued search for dual opioid agonists-NK1R antagonists, which in our hands emerged in the discovery of compound **13**, a compound which is efficacious in both acute and neuropathic pain models in mice.

MATERIALS AND METHODS

General

Thin-layer chromatography (TLC) was performed on glass plates precoated with silica gel 60F₂₅₄ (Merck, Darmstadt, Germany) using the mentioned solvent systems. Purification of organic molecules was done with flash chromatography (Davisil LC60A, 40-63 μ m). Mass Spectrometry (MS) was performed on a Micromass Q-ToF Micro spectrometer with electrospray ionisation (ESI). Data collection and spectrum analysis was done with Masslynx software. Analytical RP-HPLC was performed using a Waters 717plus autosampler, a Waters 1525 binary HPLC pump and a Waters 2487 dual absorbance wavelength detector (Milford,

MA), on a Grace (Deerfield, IL) Vydac RP C18 column (25 cm x 4.6 mm x 5 μ m) using UV detection at 215 nm. The mobile phase was a mixture of water and acetonitrile both containing 0.1% TFA. The used gradient runs from 3 to 100% acetonitrile in 20 minutes at a flow rate of 1 mL/min. Preparative RP-HPLC purification was done on a Gilson (Middleton, WI) HPLC system with Gilson 322 pumps, controlled by the software package Unipoint, and a reversed phase C18 column (Discovery®BIO SUPELCO Wide Pore C18 column, 25 cm x 2.21 cm, 5 μ m) using a gradient that increased by 1%/min of acetonitrile in water (both containing 0.1% TFA) until the product eluted. After purification, the purity of all compounds was evaluated as being more than 95% by analytical RP-HPLC. All fractions were lyophilized using a Flexy-Dry lyophilizer (FTS Systems, Warminster, PA).

Peptide synthesis

The protected tetrapeptides Boc-Dmt-D-Arg(Pbf)-Aba-Gly-OH and Boc-Dmt-D-Arg(Pbf)-Aba- β -Ala-OH were synthesized by *N*^α-Fmoc solid phase methodology on 2-chlorotrityl resin, including the construction of the Aba-constraint on solid phase by use of phthaloyl protected *ortho*-formyl phenylalanine, as described in detail previously.² After cleavage of the fully protected peptide acid, it was coupled to the corresponding benzyl amines in solution using DIC/HOBt. Final deprotection was performed with the mixture TFA/TES/H₂O (95/2.5/2.5) for 3 hours. The peptides were purified by preparative HPLC and characterized by high resolution mass spectrometry (see Supporting Information). Purity was > 95% as determined by analytical HPLC.

Functional NK1 receptor assay³⁰

Cell line and culture conditions, aequorin charging protocol: The Chinese Hamster Ovary K1 (CHO-K1) cell line, stably expressing human NK1 receptor was transfected with an apoequorin expression vector (pER2) using Fugene6 (Roche Applied Science). Transfected cells in the mid-log phase were loaded with coelenterazine and diluted 10-fold as described in detail elsewhere.²

Aequorin luminescence assay: A dilution series of peptide agonist (substance P, Sigma) ranging from 10⁻¹¹ to 10⁻⁴ M was distributed in a white 96-well plate, after which the synthetic compounds were added to these wells to obtain the desired concentrations (ranging from 10⁻⁸

1
2
3 to 10^{-4} M). A negative control sample (BSA medium only) was included in each row of the
4 96-well plate. Measurement started at the moment of injection of 50 μ l of the coelenterazine-
5 loaded cell suspension, containing 2.5×10^4 cells. Light emission was measured every second
6 for 30s after which 50 μ l of 10nM ATP solution (positive control) was injected.²
7
8
9

10 *Data Analysis:* Luminescence data (peak integration) were calculated as described previously²
11 using MikroWin 2000 software (Berthold). Statistical and curve-fitting analyses were
12 performed using Prism 4.0 (GraphPad) software. Data were expressed in percentage (% RLU)
13 of the maximal luminescence that was detected with 10^{-4} M SP (without antagonist). The
14 competitive nature of antagonism was evaluated using the Schild plot method.²² All
15 antagonists analyzed in this study provided linear regression plots and were considered
16 competitive. The pA₂ values were calculated using the Schild's equation.²²
17
18
19
20
21
22
23
24

25 **hNK1-CHO membrane preparation for binding assay**

26 The hNK1-CHO cells were cloned locally and grown in a humidified CO₂ (5%) atmosphere at
27 37 °C in a Forma Scientific incubator (Thermo Forma, Series II Water Jacketed, USA) in a
28 Dulbecco's DMEM-F12 50:50 medium (Corning Cellgro, USA) supplemented with 10%
29 heat-inactivated fetal bovine serum (Gibco, Life Technologies) and 1X PenStrep solution
30 (Gibco, Life Technologies, USA). Confluent cell monolayers were harvested with 1X
31 Dulbecco's PBS containing 5 mM EDTA. Cells were centrifuged in a Sorvall ST 16R
32 centrifuge (ThermoScientific) at 1500 rpm for 3 min. The supernatants were aspirated and the
33 remaining pellets were placed at -80°C. On the day of the experiments, cell pellets were
34 thawed and homogenized with a teflon-glass tissue homogenizer in an ice-cold 50 mM Tris-
35 HCl (pH 7.4) buffer containing 5 mM MgCl₂. The membrane fractions were collected by
36 centrifugation in a Sorvall RC 5C Plus (ThermoScientific) at 13,000 rpm for 25 min at 4°C
37 and the resulting pellets were re-suspended in 50mM Tris-HCl (pH 7.4), 5 mM MgCl₂ buffer.
38 Protein contents of the pellet suspensions were determined by the BCA method (Bio-Rad,
39 Bio-Rad Laboratories, USA).
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

[³H]Substance-P competition binding assay

The test compounds were dissolved in DMSO and stored in 10 mM aliquots at -20°C. Serial dilutions of the compounds were prepared in the binding buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl₂). Serial dilutions of the competitor ligands were co-incubated with 45 µg of membrane protein and 0.5-0.8 nM [³H]Substance-P (36.5 Ci/mmol, PerkinElmer, USA) in a final volume of 200 µl at RT for an hour. Total binding was determined in the absence of competitors while non-specific binding was defined in the presence of 10 µM Substance-P (final concentration). Substance-P (Tocris, Tocris Bioscience, UK) was also used as a control to validate the binding assay conditions. The reactions were terminated by rapid filtration onto UniFilter GF/B 96-well plates (PerkinElmer, USA), previously pre-soaked in cold 1% polyethyleneimine solution (Sigma Aldrich, USA). Plates were washed 3 times with cold water and dried at RT for overnight. Filter bound radioactivity was measured by a MicroBeta 2450 microplate reader (PerkinElmer, USA) using a microscintillation cocktail (PerkinElmer, USA).

Data analysis

Experiments were carried out in duplicate in 96-well plates, and are the average of at least three independent experiments. The IC₅₀ and K_i values for each test compound were calculated by nonlinear regression and standard error of means (S.E.M) is represented. Data analyses were performed by GraphPad Prism4 software (GraphPad, San Diego, California). The K_i was calculated using the previously determined K_d of the [³H]Substance-P in this cell line by saturation binding.

Functional GPI and MVD assays

The guinea pig ileum (GPI)³¹ and mouse vas deferens (MVD)³² bioassays were carried out as described in detail elsewhere.³³⁻³⁴ A dose-response curve was determined with [Leu⁵]enkephalin as standard for each ileum and vas preparation and IC₅₀ values of the compounds being tested were normalized according to a published procedure.³⁵

Opioid receptor binding assays

Opioid receptor binding studies were performed as described in detail elsewhere.³³ Binding affinities for MOP and DOP receptors were determined by displacing, respectively, [³H]DAMGO (Multiple Peptide Systems, San Diego, CA) and [³H]DSLET (Multiple Peptide Systems) from rat brain membrane binding sites, and κ opioid receptor binding affinities were measured by displacement of [³H]U69,593 (Amersham) from guinea pig brain membrane binding sites. Incubations were performed for 2 h at 0 °C with [³H]DAMGO and [³H]DSLET

at respective concentrations of 0.72 and 0.78 nM. IC₅₀ values were determined from log-dose displacement curves, and K_i values were calculated from the IC₅₀ values by means of the equation of Cheng and Prusoff,³⁶ using values of 1.3 and 2.6 nM for the dissociation constants of [³H]DAMGO and [³H]DSLET, respectively.

Animals

Male Albino Swiss CD-1® IGS mice (30 - 35 g) obtained from Charles River Breeding Laboratories, Germany, were housed ten mice per cage (lined with sawdust) under a standard 12/12 h light/dark cycle (lights on at 6:00 am) with food and water available *ad libitum*. All experiments were performed according to the recommendations of IASP, the NIH Guide for Care and Use of Laboratory Animals, and were approved (1214/2015) by the local Bioethics Committee (Cracow, Poland).

Neuropathic pain model

Chronic constriction injury (CCI) model was performed according to Bennet and Xie³⁷ and used in our laboratory.³⁸⁻³⁹ The surgical procedure was performed under isoflurane anesthesia. An incision was made below the mouse's right hipbone, and the sciatic nerve was exposed. Three ligatures with 4/0 silk thread were made around the nerve distal to the sciatic notch with 1 mm spacing, until a brief twitch in the respective hind limb was observed. Mice were tested for the presence of characteristics for neuropathy. All CCI mice developed allodynia and hyperalgesia. The behavioral experiments were conducted on the 7th to 14th day following the CCI surgical procedure.

Biochemical analysis

qRT-PCR analysis of gene expression – Spinal cord tissue for biochemical analysis was collected on the 7th day after the CCI. Lumbar (L4-L6) fragments of the spinal cord were removed immediately after the mice were decapitated, and both the ipsilateral and contralateral parts were dissected. The tissue samples were placed in individual tubes containing the tissue storage reagent RNAlater (Qiagen Inc.) and stored at -70°C for RNA isolation. Total RNA was extracted using TRIzol reagent (Invitrogen), as previously described. RNA concentrations and quality were measured using a NanoDropND-1000 Spectrometer (NanoDrop Technologies). Reverse transcription was performed on 1 µg of total RNA using Omniscript reverse transcriptase (Quiagen Inc.) at 37°C for 60 min. Reverse transcription (RT) reactions were carried out in the presence of an RNase inhibitor (RNasin, promega) and an oligo (dT16) primer (Quiagen Inc.). The cDNA was diluted 1:10 with water,

and for each reaction, ca. 50 ng of cDNA synthesized from the total RNA of an individual animal was used for the quantitative real-time PCR (qPCR) reaction. qPCR was performed using Assay-On-Demand TaqMan probes according to the manufacturer's protocol (Applied Biosystems), and the reactions were run on an iCycler device (BioRad, Hercules). The following TaqMan primers and probes were used: Mm00446968_m1 (Hprt, hypoxanthine guanine phosphoribosyl transferase), Mm00436892_m1 (Tac1r, NK1 receptor), Mm01166996_m1 (Tac1, substance P), Mm01188089_m1 (Oprm1, MOP receptor), Mm01180757_m1 (Oprd1, DOP receptor). The expression of Hprt was measured in the lumbar spinal cord of mice as measured on days 7 and 14 following CCI procedure and quantified to control for variations in cDNA amounts. Hprt did not significantly change for CCI-exposed mice and therefore served as an adequate housekeeping gene (data not shown). The cycle threshold values were calculated automatically by iCycler IQ 3.0 software using default parameters. The RNA abundance was calculated as $2^{-(\text{threshold cycle})}$.

Western Blot – The ipsilateral and contralateral dorsal parts of the spinal cord (L4-L6) from naïve and CCI-exposed mice (7th day after injury) were collected in RIPA (Radio-Immunoprecipitation Assay) buffer with protease and phosphatase inhibitor cocktails (Sigma-Aldrich). Tissue lysates were cleared by centrifugation (14,000× g for 30 min at 4°C) and protein concentration in the supernatant was determined using the BCA Protein Assay Kit (Sigma-Aldrich). Samples containing 25 µg of protein were heated in a loading buffer (4x Laemmli Buffer, Bio-Rad) for 5 min at 98°C and then were resolved on 4–15% Criterion™ TGX™ pre-cast polyacrylamide gels (Bio-Rad, Poland). The proteins were transferred to Immune-Blot PVDF membranes (Bio-Rad, Poland) with semi-dry transfer (30 min, 25 V) and then the membranes were blocked for 1h at RT using 5% non-fat, dry milk (Bio-Rad) in Tris-buffered saline. Next, the membranes were washed in TBST (Tris-buffered saline with 0.1% Tween-20) and incubated overnight at 4 °C with the following primary antibodies: rabbit polyclonal NK1 receptor (Novus Biologicals) 1:500; MOP receptor (Abcam) 1:500, DOP receptor (LifeSpan) 1:500 and substance P (Santa Cruz) 1:250 or mouse polyclonal GAPDH (Millipore) 1:5000. The membranes were then incubated for 1h in horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies at a dilution of 1:5000. All antibodies were diluted in the SignalBoost™ Immunoreaction Enhancer Kit (Merck Millipore Darmstadt). The membranes were washed 4 times for 5 min each with TBST. The Clarity™ Western ECL Substrate (Bio-Rad, Poland) was used to detect immunocomplexes, which were visualized using a Fujifilm LAS-4000 FluorImager system. The Fujifilm Multi Gauge

software was used to quantify the relative levels of immunoreactivity. The immunoblots shown are representative of 4–6 individual samples.

Drug administration

Three designed compounds containing both NK1 receptor antagonist and MOP and DOP receptor-agonist pharmacophores: **3** (SBCHM1), **12** (RCCHM3), **13** (RCCHM6), and the reference compounds containing only pure opioid pharmacophore: **1** (AN81) and **3** (KGOP1) were used in the study. Drugs were dissolved in water for injections (Polpharma, Poland) and administered intrathecally (i.t.) in 5 µl dose volume through lumbar puncture between L5 and L6 vertebrae to non-anesthetized mice, according to the Hylden & Wilcox model⁴⁰ described with modifications by Fairbanks.⁴¹ The i.t. injections were performed with disposable 30 gauge 1/2-inch needles (Becton Dickinson and Company, Rutherford, NJ, USA) matched to a 25-µl syringe (Hamilton, Reno, NV, USA). Behavioral tests were performed 30, 90 and 180 min after drugs administration.

Behavioral tests

Von Frey test: Mechanical sensitivity to non-noxious stimuli was measured by applying a set of calibrated nylon monofilaments (0.6 – 6 g; Stoelting), in serial increments on a tested hind paw plantar surface, until a behavioral response was observed. Responses considered as pain behavior included paw withdrawal, shaking and licking.

Cold plate test: Sensitivity to noxious thermal stimuli was assessed with usage of Cold/Hot Plate Analgesia Meter, Columbus Instruments. The temperature of the plate was kept at 2 °C, and the cut-off latency was 30 s. The mice were placed on the cold plate, and the time until the hind paw was lifted was recorded.

Tail-flick test: The threshold of nociceptive pain to a thermal stimulus was assessed by tail-flick latency determined by a tail-flick analgesic meter (Analgesia Meter; Ugo Basile, Italy). In this test, the beam of light was focused on the dorsal tail surface 1 cm from the tip of the tail. The baseline was determined at 2.5–4.5 s. The cut-off time was 9 s.

RotaRod test: The motor performance of naïve mice was assessed by the RotaRod test (Mouse Rota-Rod, Ugo Basile, Italy). Mice were placed on a horizontal rod which was rotating at accelerating speed, starting with 2 rpm and reaching 40 rpm within 300 seconds. The main experiment was conducted after 3 training sessions, lasting 300 seconds each. The time was recorded until a mouse fell off the rod. RotaRod test was conducted 30 min after drug administration.

■ Associated Content

An electronic supporting information file is available and contains chemistry procedures and compound characterization.

■ Author Contributions

JS, KPB, JM and BP were in charge of performing and designing the biochemical and animal experiments. RC, KG, AM, DT and SB have designed and prepared the hybrid opioid-NK1R ligands. NNC, CL and PS carried out and supervised the functional tissue assays (GPI and MVD). AK, JS, JVD and JVB have performed the NK1R binding and activity assays, respectively. DT, PS, SB and BP were in charge of writing and editing the manuscript.

■ Author Information

■ Corresponding Authors

Prof. Dr. Steven Ballet. Research Group of Organic Chemistry, Departments of Chemistry and Bio-engineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, B-1050 Brussels, Belgium; Tel.: 0032-26293292; Fax.: 0032-26293304; e-mail: steven.ballet@vub.be

Prof. Barbara Przewlocka. Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343, Kraków, Poland; Tel.: 0048126623398; e-mail: barbara.przewlocka@gmail.com

■ Acknowledgements

SB and DT thank the Research Foundation – Flanders for the financial support. The work of JS, KPB, JM and BP was supported by MAESTRO NCN2012/06/A/NZ4/00028 grant and statutory funds IF PAS; JS is a holder of a KNOW scholarship sponsored by the Ministry of Science and Higher Education, Poland. The work of PWS was supported by grants from the U.S. National Institute on Drug Abuse (NIH, DA004443) and the Canadian Institutes of Health Research (MOP-89716). Research performed by JVD and JVB was supported by the Interuniversity Attraction Poles (IAP) program (Belgian Science Policy Grant (P7/40)).

■ Abbreviations

Aba: 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one; CCI: chronic constriction injury; DIC: *N,N'*-diisopropylcarbodiimide, DOP: delta opioid peptide; Dmt: 2',6'-dimethyltyrosine; GPI: guinea pig ileum; HOBt: 1-hydroxybenzotriazole; MOP: mu opioid peptide; mRNA:

messenger RNA; MPE: maximum possible effect; MVD: mouse vas deferens; NK1: neurokinin-1; Pbf: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; qRT-PCR: quantitative real-time polymerase chain reaction, GAPDH - Glyceraldehyde 3-phosphate dehydrogenase.

References

1. Ballet, S.; Feytens, D.; Buysse, K.; Chung, N. N.; Lemieux, C.; Tumati, S.; Keresztes, A.; Van Duppen, J.; Lai, J.; Varga, E., Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist. *J. Med. Chem.* **2011**, *54* (7), 2467-2476.
2. Guillemyn, K.; Kleczkowska, P.; Lesniak, A.; Dyniewicz, J.; Van der Poorten, O.; Van den Eynde, I.; Keresztes, A.; Varga, E.; Lai, J.; Porreca, F., Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist-neurokinin-1 antagonist peptidomimetics. *European journal of medicinal chemistry* **2015**, *92*, 64-77.
3. Bouhassira, D.; Attal, N., Translational neuropathic pain research: a clinical perspective. *Neuroscience* **2016**, *338*, 27-35.
4. Jackson, K. C., Pharmacotherapy for neuropathic pain. *Pain practice* **2006**, *6* (1), 27-33.
5. Przewlocki, R.; Przewlocka, B., Opioids in neuropathic pain. *Current pharmaceutical design* **2005**, *11* (23), 3013-3025.
6. Vanderah, T. W., Pathophysiology of pain. *Medical Clinics of North America* **2007**, *91* (1), 1-12.
7. Kleczkowska, P.; W Lipkowski, A.; Tourwe, D.; Ballet, S., Hybrid opioid/non-opioid ligands in pain research. *Current pharmaceutical design* **2013**, *19* (42), 7435-7450.
8. Schiller, P. W., Bi-or multifunctional opioid peptide drugs. *Life Sci.* **2010**, *86* (15), 598-603.
9. Dvoracsko, S.; Stefanucci, A.; Novellino, E.; Mollica, A., The design of multitarget ligands for chronic and neuropathic pain. *Future medicinal chemistry* **2015**, *7* (18), 2469-2483.
10. Labianca, R.; Sarzi-Puttini, P.; Zuccaro, S. M.; Cherubino, P.; Vellucci, R.; Fornasari, D., Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. *Clinical drug investigation* **2012**, *32* (suppl_1 Chronic), 53.
11. Garcia-Recio, S.; Gascón, P., Biological and pharmacological aspects of the NK1-receptor. *BioMed research international* **2015**, *2015*.
12. Matsumura, T.; Sakai, A.; Nagano, M.; Sawada, M.; Suzuki, H.; Umino, M., Increase in hemokinin-1 mRNA in the spinal cord during the early phase of a neuropathic pain state. *Br. J. Pharmacol.* **2008**, *155* (5), 767-774.
13. Obara, I.; Parkitna, J. R.; Korostynski, M.; Makuch, W.; Kaminska, D.; Przewlocka, B.; Przewlocki, R., Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain. *Pain* **2009**, *141* (3), 283-291.
14. Popiolek-Barczyk, K.; Makuch, W.; Rojewska, E.; Pilat, D.; Mika, J., Inhibition of intracellular signaling pathways NF- κ B and MEK1/2 attenuates neuropathic pain development and enhances morphine analgesia. *Pharmacol. Rep.* **2014**, *66* (5), 845-851.
15. Zhou, X.-L.; Yu, L.-N.; Wang, Y.; Tang, L.-H.; Peng, Y.-N.; Cao, J.-L.; Yan, M., Increased methylation of the MOR gene proximal promoter in primary sensory neurons plays a crucial role in the decreased analgesic effect of opioids in neuropathic pain. *Molecular pain* **2014**, *10* (1), 51.
16. Kabli, N.; Cahill, C. M., Anti-allodynic effects of peripheral delta opioid receptors in neuropathic pain. *Pain* **2007**, *127* (1), 84-93.
17. Pierson, N. A.; Chen, L.; Russell, D. H.; Clemmer, D. E., Cis-trans isomerizations of proline residues are key to bradykinin conformations. *J. Am. Chem. Soc.* **2013**, *135* (8), 3186-3192.

18. Saulitis, J.; Mierke, D. F.; Byk, G.; Gilon, C.; Kessler, H., Conformation of cyclic analogs of substance P: NMR and molecular dynamics in dimethyl sulfoxide. *J. Am. Chem. Soc.* **1992**, *114* (12), 4818-4827.
19. Levian-Teitelbaum, D.; Kolodny, N.; Chorev, M.; Selinger, Z.; Gilon, C., 1H-nmr studies of receptor-selective substance P analogues reveal distinct predominant conformations in DMSO-d₆. *Biopolymers* **1989**, *28* (1), 51-64.
20. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D., Molecular properties that influence the oral bioavailability of drug candidates. *J. Med. Chem.* **2002**, *45* (12), 2615-2623.
21. Takeuchi, Y.; Shands, E. B.; Beusen, D. D.; Marshall, G. R., Derivation of a three-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor. *J. Med. Chem.* **1998**, *41* (19), 3609-3623.
22. Schild, H., pA, a new scale for the measurement of drug antagonism. *Br. J. Pharmacol.* **1947**, *2* (3), 189-206.
23. Ricardo Buenaventura, M.; Rajive Adlaka, M.; Nalini Sehgal, M., Opioid complications and side effects. *Pain physician* **2008**, *11*, S105-S120.
24. Eisenberg, E.; Suzan, E., Drug combinations in the treatment of neuropathic pain. *Current pain and headache reports* **2014**, *18* (12), 1-8.
25. Marion Lee, M.; Sanford Silverman, M.; Hans Hansen, M.; Vikram Patel, M., A comprehensive review of opioid-induced hyperalgesia. *Pain physician* **2011**, *14*, 145-161.
26. McNicol, E. D.; Midbari, A.; Eisenberg, E., Opioids for neuropathic pain. *The Cochrane Library* **2013**.
27. Misterek, K.; Maszczyńska, I.; Dorociak, A.; Gumulka, S.; Carr, D.; Szyfelbein, S.; Lipkowski, A., Spinal co-administration of peptide substance P antagonist increases antinociceptive effect of the opioid peptide buprenorphine. *Life Sci.* **1994**, *54* (14), 939-944.
28. Largent-Milnes, T.; Yamamoto, T.; Nair, P.; Moulton, J.; Hruby, V.; Lai, J.; Porreca, F.; Vanderah, T., Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. *British journal of pharmacology* **2010**, *161* (5), 986-1001.
29. Foran, S. E.; Carr, D. B.; Lipkowski, A. W.; Maszczyńska, I.; Marchand, J. E.; Misicka, A.; Beinborn, M.; Kopin, A. S.; Kream, R. M., A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic. *Proc. Natl Acad. Sci.* **2000**, *97* (13), 7621-7626.
30. Janecka, A.; Poels, J.; Fichna, J.; Studzian, K.; Broeck, J. V., Comparison of antagonist activity of spantide family at human neurokinin receptors measured by aequorin luminescence-based functional calcium assay. *Regulatory peptides* **2005**, *131* (1), 23-28.
31. Paton, W. D., The action of morphine and related substances on contraction and on acetylcholine output of coxially stimulated guinea-pig ileum. *British journal of pharmacology and chemotherapy* **1957**, *12* (1), 119-127.
32. Henderson, G.; Hughes, J.; Kosterlitz, H., A new example of a morphine-sensitive neuro-effector junction: adrenergic transmission in the mouse vas deferens. *Br. J. Pharmacol.* **1972**, *46* (4), 764-766.
33. Schiller, P. W.; Lipton, A.; Horrobin, D. F.; Bodanszky, M., Unsulfated C-terminal 7-peptide of cholecystokinin: a new ligand of the opiate receptor. *Biochem. Biophys. Res. Commun.* **1978**, *85* (4), 1332-1338.
34. DiMaio, J.; Nguyen, T. M.; Lemieux, C.; Schiller, P. W., Synthesis and pharmacological characterization in vitro of cyclic enkephalin analogs: effect of conformational constraints on opiate receptor selectivity. *J. Med. Chem.* **1982**, *25* (12), 1432-1438.
35. Waterfield, A. A.; Leslie, F. M.; Lord, J. A.; Ling, N.; Kosterlitz, H. W., Opioid activities of fragments of β -endorphin and of its leucine⁶⁵-analogue. Comparison of the binding properties of methionine- and leucine-enkephalin. *Eur. J. Pharmacol.* **1979**, *58* (1), 11-18.
36. Cheng, Y.-C.; Prusoff, W. H., Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction. *Biochem. Pharmacol.* **1973**, *22* (23), 3099-3108.
37. Bennett, G. J.; Xie, Y.-K., A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. *Pain* **1988**, *33* (1), 87-107.

- 1
2
3 38. Mika, J.; Osikowicz, M.; Rojewska, E.; Korostynski, M.; Wawrzczak-Bargiela, A.;
4 Przewlocki, R.; Przewlocka, B., Differential activation of spinal microglial and astroglial cells in a
5 mouse model of peripheral neuropathic pain. *Eur. J. Pharmacol.* **2009**, 623 (1), 65-72.
6 39. Mika, J.; Wawrzczak-Bargiela, A.; Osikowicz, M.; Makuch, W.; Przewlocka, B., Attenuation
7 of morphine tolerance by minocycline and pentoxifylline in naive and neuropathic mice. *Brain,*
8 *behavior, and immunity* **2009**, 23 (1), 75-84.
9 40. Hylden, J. L.; Wilcox, G. L., Intrathecal morphine in mice: a new technique. *Eur. J.*
10 *Pharmacol.* **1980**, 67 (2-3), 313-316.
11 41. Fairbanks, C. A., Spinal delivery of analgesics in experimental models of pain and analgesia.
12 *Advanced drug delivery reviews* **2003**, 55 (8), 1007-1041.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Graphical abstract

